PILA PHARMA AB (PILA) AI Stock Analysis

• Market Cap: kr86.94M
• Dividend Yield: N/A
• Average Volume (3M): 26.43K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.86
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: SE
• Employees: 1
• Sector: Healthcare
• Sector Strength: 59
• Industry: Biotechnology
• EPS (TTM): -0.45
• Shares Outstanding: 27,126,623
• 10 Day Avg. Volume: 28,530
• 30 Day Avg. Volume: 26,434
• PEG Ratio: -0.03
• Price to Book (P/B): 5.60
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.87
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 40 Underperform
• Price Target: ―

PILA PHARMA AB's overall score reflects significant financial challenges, including declining revenue and negative cash flow, despite a strong equity position with no debt. Technical analysis indicates a lack of momentum, and the negative valuation metrics highlight the risks associated with investing in this biotechnology firm. Improving revenue and cash flow will be crucial for future performance.

PILA PHARMA AB Business Overview & Revenue Model

Company Description

PILA PHARMA AB (PILA) is a Swedish biotechnology company focused on the research and development of novel treatments for metabolic diseases, particularly type 2 diabetes. The company leverages its expertise in the TRPV1 receptor pathway to develop innovative therapeutic solutions aimed at improving the lives of patients. PILA PHARMA is dedicated to advancing its pipeline of pharmaceutical products through rigorous clinical trials and collaborations within the healthcare industry.

How the Company Makes Money

PILA PHARMA AB generates revenue primarily through the development and commercialization of its pharmaceutical products targeting metabolic disorders. The company's revenue model includes out-licensing its drug candidates to larger pharmaceutical companies, which involves upfront payments, milestone payments, and royalties on future sales. Additionally, PILA may engage in collaborative research agreements and partnerships to fund its R&D activities, where partners contribute resources and funding in exchange for certain rights to the developed products. The success of PILA's revenue streams is heavily dependent on the successful progression of its drug candidates through clinical trials and regulatory approval processes.

PILA PHARMA AB Financial Statement Overview

Summary

PILA PHARMA AB faces financial headwinds with declining revenue, persistent losses, and negative cash flows. Despite a strong equity base and no debt, the company's financial performance reflects operational and market challenges typical in the biotechnology industry. Future sustainability will depend on improving revenue streams and managing cash outflows efficiently.

Income Statement

The company shows a declining revenue trend, with total revenue decreasing from 1,463,020 in 2023 to 775,000 in 2024. Gross profit margins have been consistently low, reflecting operational challenges. The net profit margin remains negative due to continued losses. EBIT and EBITDA margins are also deeply negative, indicating significant operational inefficiencies.

Balance Sheet

PILA PHARMA AB maintains a strong equity position with a debt-to-equity ratio of zero, reflecting no reliance on debt financing. However, the company's equity ratio has declined over the years, and total assets have decreased as well. While the cash position appears healthy, diminishing stockholders' equity and assets pose potential risks.

Cash Flow

The company struggles with negative free cash flow, which increased from -4,854,000 in 2023 to -7,823,000 in 2024. Operating cash flow remains negative, though financing activities have provided some cash inflow. The free cash flow to net income ratio indicates that operational cash generation is not covering losses, challenging future liquidity.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
1.05M	775.00K	1.46M	1.88M	719.23K	0.00
	Gross Profit
-4.20M	-8.12M	1.46M	-8.89M	680.94K	-492.39K
	EBIT
-6.88M	-8.11M	-6.39M	-8.89M	-9.26M	-3.38M
	EBITDA
-5.80M	-10.11M	-8.81M	-26.76M	-17.16M	-3.36M
	Net Income Common Stockholders
-6.92M	-11.24M	-9.93M	-44.66M	-25.15M	-10.58M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.54M	4.89M	5.95M	7.24M	28.21M	1.91M
	Total Assets
4.49M	6.22M	8.46M	10.89M	31.81M	5.37M
	Total Debt
0.00	0.00	773.08K	0.00	0.00	500.00K
	Net Debt
-2.54M	-4.89M	-5.95M	-7.24M	-28.21M	-1.41M
	Total Liabilities
1.91M	963.00K	1.79M	1.36M	1.51M	1.95M
	Stockholders Equity
2.58M	5.26M	6.66M	9.53M	30.30M	3.42M
Cash Flow		Free Cash Flow
-4.96M	-7.82M	-4.85M	-9.09M	-9.36M	-2.00M
	Operating Cash Flow
-4.96M	-7.82M	-4.85M	-9.09M	-9.36M	-2.00M
	Investing Cash Flow
0.00	0.00	0.00	0.00	0.00	0.00
	Financing Cash Flow
7.06M	6.76M	3.56M	-11.88M	35.67M	-158.07K

PILA PHARMA AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:PILA, the sentiment is Positive. The current price of 3.2 is above the 20-day moving average (MA) of 3.08, above the 50-day MA of 3.07, and below the 200-day MA of 4.03, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 65.30 is Neutral, neither overbought nor oversold. The STOCH value of 65.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:PILA.

PILA PHARMA AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.38B	3.27	-45.10%	3.30%	16.81%	0.02%
BIOVIC.B	51 Neutral	kr64.33M	―	-104.90%	―	36.91%	49.66%
ONCOZ	41 Neutral	€77.78M	―	-46.84%	―	―	45.38%
PILA	40 Underperform	kr86.94M	―		―	―	―
SPAGO	38 Underperform	kr74.51M	―	-105.78%	―	58.72%	70.69%
BIOSGN	34 Underperform	kr144.65M	―	-56.71%	―	―	35.61%
ACTI	32 Underperform	kr293.39M	―	-186.40%	―	―	24.47%